AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06452953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone 1 mg
Description: Eszopiclone is used in the treatment of various types of insomnia.
Study NCT02856425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
Study NCT02856425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
Study NCT00192699 — intervention group
Intervention type: DEVICE
Intervention: Bimetric femoral stem
Description: Cemented Bi-Metric femoral stem
Study NCT02427607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
Study NCT02729688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: customized pressure guide bandage
Description: Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
Study NCT02729688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary elastic bandage
Description: Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
Study NCT00819728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35mg/m2 IV each week for 4 weeks
Study NCT00819728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2 IV each week for 4 weeks
Study NCT05377957 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: Collection of patient-reported outcomes concerning general and health-related quality of life and impact of uveal melanoma diagnosis
Study NCT05377957 — intervention group
Intervention type: OTHER
Intervention: Discrete choice experiment
Description: Assessment of patient preferences for outcomes of proton therapy and enucleation
Study NCT05377957 — intervention group
Intervention type: OTHER
Intervention: Shared decision-making analysis
Description: Assessment of shared decision-making from the perspective of the patient (by questionnaire), physician (by questionnaire) and a neutral observer (by audiotape), combined with patient-reported satisfaction and regret of the treatment decision (by questionnaire)
Study NCT05377957 — intervention group
Intervention type: OTHER
Intervention: Impact of side-effects analysis
Description: Assessment of the impact of side-effects by questionnaire
Study NCT02910700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO
Study NCT02910700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO
Study NCT02910700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO
Study NCT02910700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02910700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02910700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02910700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT04755881 — intervention group
Intervention type: OTHER
Intervention: Occurence of biphasic reaction following anaphylaxis
Description: Prospective observation for biphasic reaction following anaphylaxis and subsequent analysis (comparison between usual care and the care that would have been suggested by the three proposed clinical decision rules).
Study NCT03987438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with APP
Description: The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
Study NCT02292238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benfotiamine
Description: * To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate.
Study NCT02292238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benfotiamine
Description: * To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~* To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate.
Study NCT01789320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide (Triesence®)
Description: 4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
Study NCT03706638 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ferrous Sulfate
Description: Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
Study NCT03830528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Low Dose
Description: KW-6356 will be administered as single doses.
Study NCT03830528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Middle Dose
Description: KW-6356 will be administered as single doses.
Study NCT03830528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 High Dose
Description: KW-6356 will be administered as single doses.
Study NCT03830528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 X Dose
Description: KW-6356 will be administered as multiple doses.
Study NCT03830528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356 Y Dose
Description: KW-6356 will be administered for Japanese healthy men as multiple doses.
Study NCT03830528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All study cohorts (except Part C) are placebo controlled.
Study NCT06666920 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: laser irradiation
Description: Immediately after applying the bleaching agent, the gel on the left upper and lower hemiarches (teeth 21-25 and 31-35) was irradiated using an Er,Cr:YSGG laser (2780 nm). Specifically, an Er,Cr:YSGG solid-state laser device (Waterlase MD Turbo, BIOLASE, Irvine, CA, USA) equipped with a Z-type glass tip (MZ8) measuring 800 μm in diameter and 6 mm in length was used. This tip was attached to the laser system's gold handpiece. The laser parameters for the treatment included an average output power of 1.25 W, a pulse duration of 700 μs (S-mode), and a pulse repetition rate of 10 Hz, without water or air flow, according to a previous study. Each tooth received two 15-s irradiation intervals, one for each 20-min session (totaling 30 s), while maintaining the laser handpiece approximately 2.5 cm from the tooth surface, perpendicular to the enamel. The gel was irradiated using a scanning mode, with the handpiece moved slowly in both horizontal and vertical directions at a speed of 2 mm/s.
Study NCT06666816 — intervention group
Intervention type: OTHER
Intervention: inapplicable
Description: inapplicable
Study NCT02381730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Description: Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
Study NCT03361995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Procedure using the ZOLL Thermogard XP3 IVTM System
Description: Cooling Procedure with ZOLL Thermogard XP3 IVTM System before and after Percutaneous Coronary Intervention (PCI)
Study NCT03361995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Standard of Care for PCI
Study NCT03361995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Standard of Care for PCI
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Receive DVD
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: Receive DVD
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04622670 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT02463344 — intervention group
Intervention type: BIOLOGICAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
Study NCT03752788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task Training Fixed Priority
Description: Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words.
Study NCT00323401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antenatal classes
Description: 3 sessions of 3 hours each
Study NCT04622670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Attend yoga class
Study NCT02563002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
Study NCT02563002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
Study NCT02563002 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02563002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03752788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task Training Variable Priority
Description: Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks.
Study NCT04158674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
Study NCT04158674 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cernevit
Description: mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
Study NCT02563002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion
Study NCT02563002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: IV infusion
Study NCT02162771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Study NCT02162771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02162771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Study NCT00924209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m\^2 dose for two doses on days 1 and 8
Study NCT00924209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 on day 1
Study NCT00924209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7.5 mg/m\^2 on day 1 every 21 days for first two cycles only
Study NCT00924209 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
Study NCT02013388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO daily for 14 days
Study NCT02013388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO daily for 14 days
Study NCT02013388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N91115
Description: Given PO only on Day 1
Study NCT02013388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Day 1 only
Description: Given PO- only on Day 1 (single dosed to match single dose treatments)
Study NCT00924209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
Study NCT00735501 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Study NCT01674309 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFORINOX
Description: INTRAVENOUS administration
Study NCT03685396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin ( PRF)
Description: Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site.
Study NCT03685396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hemostatic agents with oxidized and regenerated cellulosa
Description: In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
Study NCT02768610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02768610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01889173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablets at 2.8 mg
Description: 1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
Study NCT01889173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102-B SL Tablets at 2.8 mg
Description: 1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
Study NCT01889173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102-C SL Tablets at 2.8 mg
Description: 1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
Study NCT01889173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine tablets
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Study NCT02401464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536 Tablet
Description: TAK-536 10 mg tablet
Study NCT03154684 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STARK intervention
Description: The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~* Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~* Inspection of the environment at the patient's home~* Care and autonomy support~* Social life support~* Secondary prevention strategies:~* Home exercise program (3x/weeks)~* Protein enriched food preparation (20g whey protein/day)~* Support to take vitamin D supplementation (2000 IU/day)~* Recommendation and support to eat calcium rich foods~* Motivation to be physically active
Study NCT03154684 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
Study NCT03377959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Mat Classes
Description: The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
Study NCT02497781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime -avibactam
Description: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
Study NCT02497781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime
Description: Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
Study NCT00745095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
Study NCT02529059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eviplera
Description: A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
Study NCT00858195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 75mg Extended-Release Capsules, Sandoz